Literature DB >> 11739150

Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation.

J Storek1, A Joseph, G Espino, M A Dawson, D C Douek, K M Sullivan, M E Flowers, P Martin, G Mathioudakis, R A Nash, R Storb, F R Appelbaum, D G Maloney.   

Abstract

The duration of immunodeficiency following marrow transplantation is not known. Questionnaires were used to study the infection rates in 72 patients surviving 20 to 30 years after marrow grafting. Furthermore, in 33 of the 72 patients and in 16 donors (siblings who originally donated the marrow) leukocyte subsets were assessed by flow cytometry. T-cell receptor excision circles (TRECs), markers of T cells generated de novo, were quantitated by real-time polymerase chain reaction. Immunoglobulin G(2) (IgG(2)) and antigen-specific IgG levels were determined by enzyme-linked immunosorbent assay. Infections diagnosed more than [corrected] 15 years after transplantation occurred rarely. The average rate was 0.07 infections per patient-year (one infection every 14 years), excluding respiratory tract infections, gastroenteritis, lip sores, and hepatitis C. The counts of circulating monocytes, natural killer cells, B cells, CD4 T cells, and CD8 T cells in the patients were not lower than in the donors. The counts of TREC(+) CD4 T cells in transplant recipients younger than age 18 years (at the time of transplantation) were not different from the counts in their donors. In contrast, the counts of TREC(+) CD4 T cells were lower in transplant recipients age 18 years or older, even in those with no history of clinical extensive chronic graft-versus-host disease, compared with their donors. The levels of total IgG(2) and specific IgG against Haemophilus influenzae and Streptococcus pneumoniae were similar in patients and donors. Overall, the immunity of patients surviving 20 to 30 years after transplantation is normal or near normal. Patients who received transplants in adulthood have a clinically insignificant deficiency of de novo-generated CD4 T cells, suggesting that in these patients the posttransplantation thymic insufficiency may not be fully reversible.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739150     DOI: 10.1182/blood.v98.13.3505

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

Review 1.  Hematopoietic stem cell transplantation: a primer for the primary care physician.

Authors:  Chantal S Léger; Thomas J Nevill
Journal:  CMAJ       Date:  2004-05-11       Impact factor: 8.262

Review 2.  Adoptive precursor cell therapy to enhance immune reconstitution after hematopoietic stem cell transplantation.

Authors:  J L Zakrzewski; A M Holland; M R M van den Brink
Journal:  J Mol Med (Berl)       Date:  2007-02-28       Impact factor: 4.599

3.  Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation.

Authors:  Hiroto Inaba; Christine M Hartford; Deqing Pei; Meredith J Posner; Jie Yang; Randall T Hayden; Ashok Srinivasan; Brandon M Triplett; Jon A McCulllers; Ching-Hon Pui; Wing Leung
Journal:  Br J Haematol       Date:  2011-10-24       Impact factor: 6.998

Review 4.  Post-transplant adoptive T-cell immunotherapy.

Authors:  Nicole A Aqui; Carl H June
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

5.  Rapidly proliferating CD44hi peripheral T cells undergo apoptosis and delay posttransplantation T-cell reconstitution after allogeneic bone marrow transplantation.

Authors:  S Onder Alpdogan; Sydney X Lu; Neel Patel; Suzanne McGoldrick; David Suh; Tulin Budak-Alpdogan; Odette M Smith; Jeremy Grubin; Christopher King; Gabrielle L Goldberg; Vanessa M Hubbard; Adam A Kochman; Marcel R M van den Brink
Journal:  Blood       Date:  2008-09-24       Impact factor: 22.113

6.  Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation.

Authors:  Raphael Itzykson; Marie Robin; Helene Moins-Teisserenc; Marc Delord; Marc Busson; Aliénor Xhaard; Flore Sicre de Fontebrune; Régis Peffault de Latour; Antoine Toubert; Gérard Socié
Journal:  Haematologica       Date:  2014-09-26       Impact factor: 9.941

7.  Myc and AP-1 expression in T cells and T-cell activation in patients after hematopoietic stem cell transplantation.

Authors:  Shivtia Trop-Steinberg; Yehudith Azar; Rachel Bringer; Reuven Or
Journal:  Clin Exp Med       Date:  2014-08-07       Impact factor: 3.984

Review 8.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

Review 9.  Immunologic approaches for the treatment of multiple myeloma.

Authors:  Leo Rasche; Niels Weinhold; Gareth J Morgan; Frits van Rhee; Faith E Davies
Journal:  Cancer Treat Rev       Date:  2017-04-06       Impact factor: 12.111

10.  Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation.

Authors:  Maxim Norkin; Bronwen E Shaw; Ruta Brazauskas; Heather R Tecca; Helen L Leather; Juan Gea-Banacloche; Rammurti T Kamble; Zachariah DeFilipp; David A Jacobsohn; Olle Ringden; Yoshihiro Inamoto; Kimberly A Kasow; David Buchbinder; Peter Shaw; Peiman Hematti; Raquel Schears; Sherif M Badawy; Hillard M Lazarus; Neel Bhatt; Biljana Horn; Saurabh Chhabra; Kristin M Page; Betty Hamilton; Gerhard C Hildebrandt; Jean A Yared; Vaibhav Agrawal; Amer M Beitinjaneh; Navneet Majhail; Tamila Kindwall-Keller; Richard F Olsson; Helene Schoemans; Robert Peter Gale; Siddhartha Ganguly; Ibrahim A Ahmed; Harry C Schouten; Jane L Liesveld; Nandita Khera; Amir Steinberg; Ami J Shah; Melhem Solh; David I Marks; Witold Rybka; Mahmoud Aljurf; Andrew C Dietz; Usama Gergis; Biju George; Sachiko Seo; Mary E D Flowers; Minoo Battiwalla; Bipin N Savani; Marcie L Riches; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2018-10-02       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.